首页> 外国专利> MULTIPHASIC CONTRACEPTIVE REGIMEN FOR ORAL COMBINATION DRUG FORMULATION OF PROGESTIN AND ESTROGEN

MULTIPHASIC CONTRACEPTIVE REGIMEN FOR ORAL COMBINATION DRUG FORMULATION OF PROGESTIN AND ESTROGEN

机译:前列腺素与雌激素经口组合用药的多相避孕法

摘要

A method for contraception includes administering to a female daily, in a fourphasic dosing regimen during a time period of 24 successive days, an oral combination drug formulation of norethindrone acetate and ethinyl estradiol (EE), wherein doses in the second, third and fourth phases of the regimen increase by a predefined dose increment as compared to the corresponding doses administered during the previous phase, wherein the norethindrone acetate dose in the first phase is 1000 mcg, in the second phase is 1125 mcg, in the third phase is 1250 mcg, and in the fourth phase is 1375 mcg, wherein the EE dose in the first phase is 20 mcg, in the second phase is 22.5 mcg, in the third phase is 25 mcg, and in the fourth phase is 27.5 mcg, and wherein the fourphasic dosing regimen is followed by 4 days without norethindrone acetate and EE administration.
机译:一种避孕方法包括在连续24天的时间段内以四阶段给药方案每天向女性给药乙酸炔诺酮和乙炔雌二醇(EE)的口服联合药物制剂,其中在第二,第三和第四阶段的剂量与前一阶段的相应剂量相比,该方案的治疗方案增加了预定的剂量增量,其中第一阶段的乙酸炔诺酮乙酸酯剂量为1000 mcg,第二阶段为1125 mcg,第三阶段为1250 mcg,第四阶段为1375 mcg,其中第一阶段的EE剂量为20 mcg,第二阶段为22.5 mcg,第三阶段为25 mcg,第四阶段为27.5 mcg,其中四相给药方案后为4天,不使用乙酸炔诺酮和EE。

著录项

  • 公开/公告号US2019022109A1

    专利类型

  • 公开/公告日2019-01-24

    原文格式PDF

  • 申请/专利权人 ARSTAT INC.;

    申请/专利号US201816139515

  • 发明设计人 ARKADY RUBIN;

    申请日2018-09-24

  • 分类号A61K31/567;A61K31/57;A61K9;A61K31/565;

  • 国家 US

  • 入库时间 2022-08-21 12:06:45

相似文献

  • 专利
  • 外文文献
  • 中文文献
获取专利

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号